Merck & Company Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: MRK Category:


Merck & Co.: Progress in Personalized Cancer Vaccine Collaborated with Moderna 


In the first quarter of 2024, Merck & Co. demonstrated a strong start with robust growth across its business. This was mainly led by the oncology and vaccines segments, where sales of KEYTRUDA and GARDASIL respectively saw significant increases. Merck’s first quarter results reflect the robust demand for its innovative portfolio, which has led to the company updating their full year guidance. One of the company’s notable achievements includes the FDA approval of WINREVAIR, a first-in[1]class treatment for adults with pulmonary arterial hypertension. The prescriptive written evidence for this treatment validates Merck’s strategic priorities and belief system, rendering tangible benefits for both patients and the company in the long run.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!